DCA has a decades-long safety record in clinical use for rare metabolic disorders, particularly in paediatric patients. Understanding its safety profile honestly — neither minimising risks nor overstating them — is essential for anyone researching this compound.

Peripheral neuropathy is the most consistently reported side effect in extended DCA use. It manifests as tingling, numbness, or pain in the extremities — typically beginning in the hands and feet. It is both dose-dependent and duration-dependent: higher doses and longer continuous use increase risk. Importantly, it is generally reversible upon cessation. The cycle protocol (2 weeks on, 1 week off) was developed specifically to minimise this risk.

DCA inhibits the thiamine-dependent enzyme PDHC over time, which may contribute to neuropathy. For this reason, many researchers reference B1 (thiamine) supplementation as a protective measure during extended DCA protocols.

Liver function should be monitored in long-term use. Elevated liver enzymes have been reported in some subjects in clinical trials, typically at higher doses.

DCA has no reported cardiac, pulmonary, renal, or bone marrow toxicity at research-relevant doses. It does not suppress the immune system. It is water-soluble with a relatively short half-life.

At AuraDCA, MCA testing is mandatory for every batch — because the risk from MCA contamination is more immediate and more serious than the known risks of pure DCA itself.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.